UNUSUAL ADVERSE DRUG REACTIONS IN HIGH GRADE GLIOMA PATIENTS TREATED WITH TEMOZOLOMIDE

被引：0

作者：

Lisa, Boris ^{[1
]}

Vera, Elizabeth ^{[2
]}

Wu, Jing ^{[3
]}

Park, Deric M. ^{[4
]}

Bryla, Christine ^{[3
]}

Crandon, Sonja ^{[5
]}

Garren, Nancy ^{[1
]}

Mccoy, Ann ^{[3
]}

Siegel, Christine ^{[5
]}

Theeler, Brett J. ^{[6
]}

Sul, Joo-Hee ^{[7
]}

Gilbert, Mark ^{[3
]}

Armstrong, Terri ^{[5
]}

机构：

[1] NCI, NIH, Bethesda, MD 20892 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] NCI, Neurooncol Branch, NIH, Bethesda, MD 20892 USA

[4] NCI, Neurooncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[5] NIH, Neurooncol Branch, Bldg 10, Bethesda, MD 20892 USA

[6] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA

[7] US FDA, Silver Spring, MD USA

来源：

NEURO-ONCOLOGY | 2017年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

QLIF-03

引用

页码：201 / 201

页数：1

共 50 条

[21] Patterns of Salvage Treatment for High Grade Glioma in Patients Who Received Upfront Temozolomide
Escorcia, F. E.
Spratt, D. E.
Folkert, M. R.
Zumsteg, Z. S.
Chan, T. A.
Omuro, A. M.
Gutin, P. H.
Yamada, Y.
Beal, K.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E113 - E114
[22] FATAL OUTCOME OF TEMOZOLOMIDE-INDUCED BONE MARROW APLASIA IN TWO PATIENTS TREATED WITH CONCURRENT CHEMORADIATION FOR HIGH GRADE GLIOMA
Novotny, J.
Svancarova, R.
Sochor, M.
ANNALS OF ONCOLOGY, 2010, 21 : 335 - 335
[23] Tp53 as a potential therapeutic biomarker in patients with recurrent high-grade glioma treated with anlotinib and temozolomide.
Wang, Chao-Jie
Yin, Ming-Mei
Zhao, Zheng
Zhang, Meng-Yi
Zhao, Wei-Feng
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[24] PATTERNS OF SALVAGE TREATMENT FOR HIGH GRADE GLIOMA IN THE TEMOZOLOMIDE ERA
Escorcia, Freddy E.
Folkert, Michael R.
Spratt, Daniel E.
Zumsteg, Zachary
Chan, Timothy
Omuro, Antonio M.
Beal, Kathryn
Gutin, Philip H.
Yamada, Josh
NEURO-ONCOLOGY, 2014, 16
[25] Adverse drug reactions in patients treated with intravenous immunoglobulins (IVIGs)
Agusti, A.
Vallano, A.
Mendoza, G.
Danés, I.
Laredo, L.
Calvo, A.
Ruiz, B.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 99 : 41 - 41
[26] Randomized feasibility study of temozolomide chronotherapy for high grade glioma
Campian, Jian Li
Talcott, Grayson
Meyer, Melissa
Slat, Emily
Avvaru, Chai
Bhatta, Puspanjali
Rubin, Joshua
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[27] Temozolomide and radiotherapy in high grade glioma: a single department experience
Iori, Cristiana
Tagliagambe, Angiolo
Piacentini, Giorgio
Marchetti, Vania
Luxardo, Sergio
Mambrini, Andrea
Del Freo, Alfonso
Massetani, Roberto
Vannozzi, Riccardo
Cantore, Maurizio
ANNALS OF ONCOLOGY, 2004, 15 : 208 - 208
[28] Temozolomide in patients with high grade gliomas
Brandes, AA
Pasetto, LM
Vastola, F
Monfardini, S
ONCOLOGY, 2000, 59 (03) : 181 - 186
[29] Unusual and Interesting Adverse Cutaneous Drug Reactions
Masatkar, Vaishali
Nagure, Ashok
Gupta, Lalit Kumar
INDIAN JOURNAL OF DERMATOLOGY, 2018, 63 (02) : 107 - 116
[30] THE ADVERSE IMPACT OF TEMOZOLOMIDE THERAPY AT INITIAL DIAGNOSIS OF GRADE II GLIOMA ON OVERALL SURVIVAL
Zhang, Ben
Decker, Paul
Kizilbash, Sani
NEURO-ONCOLOGY, 2016, 18 : 53 - 53

← 1 2 3 4 5 →